Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2010 Jun 1;107(22):9921-2.
doi: 10.1073/pnas.1005138107. Epub 2010 May 21.

Vinpocetine as a potent antiinflammatory agent

Alexandre E Medina  1
Affiliations
Comment

Vinpocetine as a potent antiinflammatory agent

Alexandre E Medina. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Mechanisms of vinpocetine action. (A) Adenylyl cyclase activity increases cAMP levels, activating PKA. Active forms of PKA may translocate to the nucleus and phosphorylate CREB. Similarly, guanylyl cyclase activity increases cGMP levels, activating the Ras/Raf pathway either directly or through PKG. This leads to the activation of ERK and the phosphorylation of both CREB and SRF. Because PDE1 catalyzes the hydrolysis of cAMP and cGMP, its inhibition by vinpocetine increases the level of these cyclic nucleotides, ultimately leading to the expression of plasticity-related genes. (B) In its inactive state, NFκB is located in the cytoplasm attached to its inhibitory subunit IκB. Inflammatory signals activate the IKK complex, which in turn phosphorylates IκB. IκB phosphorylation leads to its ubiquitination (and eventual degradation) by ubiquitin enzymes (UE). Without IκB, NFκB translocates to the nucleus, where it phosphorylates κB sites in many genes, which results in the expression of many proinflammatory molecules. Vinpocetine blocks IKK activity, preventing NFκB-triggered protein expression.
See this image and copyright information in PMC

Comment on

References

    1. Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009;103:975–994. - PubMed
    1. Jeon K-I, et al. Vinpocetine inhibits NF-κB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci USA. 2010;107:9795–9800. - PMC - PubMed
    1. Balestreri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc. 1987;35:425–430. - PubMed
    1. Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003;1:CD003119. - PMC - PubMed
    1. DeNoble VJ. Vinpocetine enhances retrieval of a step-through passive avoidance response in rats. Pharmacol Biochem Behav. 1987;26:183–186. - PubMed

Publication types

MeSH terms

LinkOut - more resources